Innovation
Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office
22 June 2022
Since the Office of Health Economics (OHE) published a critique of CBO’s new simulation model of new drug development late last year, the U.S. public sector…
Invest to End TB. Save Lives. World TB Day 2022. Reflections on 60 years of OHE publications on TB
24 March 2022
Global TB deaths are increasing. CGD and OHE set out a “Market-Driven, Value-Based, Advance Commitment (MVAC)” that would create and guarantee a market for a breakthrough…
Rare Disease Day 2022
28 February 2022
World Rare Disease Day aims to raise awareness of rare diseases and the impact they can have on patients. This blog explores OHE’s contributions to research…
How Does Pharmaceutical Spending Drive Innovation in Europe?
7 February 2022
A new publication by Kourouklis and Gandjour (2022) investigates the impact of pharmaceutical spending on domestic early-stage pharmaceutical innovation in Europe. They find that European spending…
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers
1 June 2022
In recent years, U.S. policymakers have been considering reforms to tackle high and rising prescription drug spending, including unprecedented direct limits on prices and price growth…
Would Waiving COVID-19 Vaccines Patents Save Lives?
18 May 2021
This blog discusses the rationale behind a COVID-19 patent waiver decision and contributes to the current debate by producing a balanced view on the benefits and…
Key Learnings From COVID-19: The Importance of Portfolio Management and How to Procure, Pay For, Distribute, and Use Vaccines During a Pandemic
21 April 2021
In this blog, we reflect on some of the key learnings from the recent pull and push strategies to develop COVID-19 vaccines in the UK, the…
Does Government Funding Increase Public Sector Development of New Medicines?
5 March 2021
A new paper, published last week in Applied Economics, by Dimitrios Kourouklis, Senior Economist at OHE, looks at the question of whether government funding increases public…
Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
1 December 2021
Outcome-based payment (OBP) is a flexible payment mechanism linking the price the NHS pays for a medicine to the outcomes it achieves in practice for NHS…